Therapeutic Protein Clusters via Biodegradable Cross-Linkers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering protein therapeutics face limitations due to intrinsic instability, immunogenicity, and short half-life, with existing approaches like genetic fusion and engineered carriers being inefficient or reducing bioactivity.
Innovation Solution
Development of protein clusters or 'backpacks' composed of therapeutic protein monomers reversibly cross-linked by biodegradable linkers, which can be loaded onto cells for targeted delivery, allowing for controlled release of therapeutic proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If protein therapeutics are delivered using engineered carriers (encapsulation/adsorption or conjugation), then delivery efficiency is improved, but bioactivity is reduced
Solution Approach 1:
The invention divides the therapeutic protein into multiple monomers that self-assemble into clusters. Each monomer retains its bioactivity while the clustered form enables efficient delivery. The segmentation allows the therapeutic to function both as individual active units and as a collective delivery system.
Solution Approach 2:
The protein clusters are designed to be dynamic and reversible, allowing them to assemble for delivery and disassemble to release active monomers at the target site. This dynamic behavior enables the system to transition between delivery-efficient clustered form and bioactive monomeric form.
2Reliability
If protein therapeutics are used in their native form, then bioactivity is maintained, but stability and half-life are reduced
Solution Approach 1:
Multiple protein monomers are merged into clustered assemblies that provide enhanced stability and half-life compared to individual monomers. The clustering protects the monomers from degradation while maintaining their ability to function when released.
Solution Approach 2:
The invention creates composite protein cluster structures where multiple monomers are organized in specific arrangements. These composite structures combine the stability benefits of aggregation with the bioactivity of individual monomers, achieving both properties simultaneously.
3Quantity of substance
If protein therapeutics are administered systemically, then broad coverage is achieved, but side effects increase
Solution Approach 1:
The protein clusters are designed to maintain their clustered form during circulation and only disassemble at the target site or upon cellular uptake. This localized activation ensures that the therapeutic effect is concentrated where needed, reducing systemic exposure and side effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient, safe, and effective delivery of biologically active agents to cells, enhancing the therapeutic function of transferred cells and improving cancer treatment efficacy while minimizing systemic side effects.
Implementation Method 1
biodegradable cross-linkers each having two, three or four functional groups capable of reacting with nucleophilic groups on the therapeutic protein monomers, thereby cross-linking the therapeutic protein monomers into the protein cluster
Implementation Method 2
the cross-linker degrades, after administration into a subject in need thereof, under physiological conditions so as to release the therapeutic protein monomers from the protein cluster
Implementation Method 3
the protein cluster has a size between 30 nm and 1000 nm in diameter measured by dynamic light scattering
Data Source
AI summary
Disclosed herein are compositions and methods for preparation and use of protein therapeutics, and more particularly protein clusters or backpacks having a plurality of therapeutic protein monomers reversibly crossed-linked by biodegradable linkers.